7th February
2025
Cambridge Cognition Holdings
plc
("Cambridge Cognition" or the "Company")
Board
appointment
Cambridge Cognition Holdings plc (AIM: COG), the
brain health software group specialising in digital products that
advance brain health research and treatment, is pleased to announce
the appointment of Jonathan ("Jon") Kempster as an independent
Non-Executive Director of the Company, with immediate effect.
Jon has more than 20 years' experience as a public
company director and is currently a Non-Executive Director of three
AIM quoted companies: Norman Broadbent plc, a leading Executive
Search and Interim Management firm, Synthetics plc, a leader in
advanced security and surveillance systems, and Pennant
International Group plc, a systems support and training solutions
company.
Jon qualified as a chartered accountant with Price
Waterhouse in 1990 and has been CFO of a number of companies
including FII Group plc, Linden Homes, Delta plc, and Frasers
Group. He has held several non-executive roles since 2019.
This appointment further strengthens the Board by
adding additional investor relations and financial expertise and,
in taking the number of non-executive directors to six, provides
strengthened governance and ensuring robust succession planning for
possible future rotation of Board members.
Dr Steven Powell,
Chairman of Cambridge Cognition, commented:
"On behalf of the
Board, I am delighted to welcome Jon to Cambridge Cognition. His
broad experience and deep financial expertise will be a valuable
addition to the Company as we continue to build and grow the
business."
Further
information:
The following additional information
is provided in accordance with Rule 17 and Schedule Two Paragraph
(g) of the AIM Rules for Companies:
Jonathan (Jon) Kempster, aged 62,
holds or has held the following directorships in the last five
years:
|
Current directorships
|
Past
directorships within the last five years
|
|
Norman Broadbent plc
|
DX (Group) Limited
|
|
Pennant International Group
plc
|
Bonhill Group plc
|
|
Synectics plc
|
Independent Trustee Services
Limited
|
|
JVM AG
|
Ted Baker Holdings
Limited
|
|
JVM Property AG
|
Redcentric plc
|
|
Rochester Associates Ltd
|
FireAngel Safety Technology Group
plc
|
|
Delta Pension Nominees
Limited
|
FireAngel Safety Technology
Limited
|
|
|
Portcentric Solutions
Limited
|
|
|
Serinus Energy plc
|
|
|
Prosped Solutions OU
|
Jonathan Kempster does not have any
interest in any ordinary shares of the Company.
Save for the information disclosed
above, there is no other information in relation to Jonathan
Kempster that is required to be disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AІM Rules
for Companies.
Enquiries:
|
Cambridge Cognition
Holdings plc
|
Tel: 012 2381
0700
|
|
Rob Baker, Chief Operating Officer and Joint Managing
Director
|
|
|
|
|
|
Panmure Liberum
Limited (NOMAD and Joint Broker)
|
Tel: 020 7886
2968
|
|
Will Goode / Freddy Crossley / Mark Rogers
|
(Corporate
Broking)
|
|
Rupert Dearden
|
(Corporate
Broking)
|
|
|
|
|
Dowgate Capital
Limited (Joint Broker)
|
Tel: 020 3903
7715
|
|
David Poutney / James Serjeant
|
|
|
|
|
|
Hudson Sandler
(Financial PR and IR)
|
Tel: 020 7796
4133
|
|
Dan de Belder / Hattie Dreyfus / Harry Griffiths
|
cog@hudsonsandler.com
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a brain
health software group specializing in digital health products that
advance brain health research and treatment. The company offers
four core products: CANTAB® assessments-providing scientifically
validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural
networks; a flexible and proven eCOA platform with an extensive
library of instruments, enabling efficient study setup and scalable
data capture; rater training services that standardise assessment
delivery and scoring across clinical trials and quality assurance
tools that ensure data integrity by automatically detecting
deviations in administration and scoring, saving time and money.
These products collectively improve clinical trial outcomes, enable
early patient identification, and enhance global efficiency in
healthcare and pharmaceuticals.
For further information,
visit:
www.cambridgecognition.com